The global neurological biomarkers market revenue was around US$ 7.39 billion in 2022 and is estimated to reach US$ 22.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 13% during the forecast period from 2023 to 2031.
Neurological biomarkers are an identifiable compound mainly present in cerebrospinal (CSF) fluid when there has been a brain injury. These biomarkers play an important role in the earlier drug development, advancement of personalized medicine, and diagnosis of neurological disorders.
Market Driving Factors
Current advancements in biomarkers, such as biomarker signatures, make neurological diseases more treatable. This has resulted in faster drug development, early diagnosis, and non-invasive testing. In addition, digital biomarkers provide several pharmaceutical companies with supplemental data to conclude clinical trial decisions. The Stroke and National Institute of Neurological Disorders provides funding, such as development grants and cooperative agreements for researchers conducting studies associated with analytical validation, biomarker discovery, and clinical validation. Therefore, this factor drives the market expansion.
Biomarker research in neurodegenerative disease is a massive advancing area in personalized medicine. Numerous molecules have been associated and assessed with various neurodegenerative disorders. This change within precision medicine has affected the biopharmaceutical industry. In addition, various players from biopharma to diagnostics companies with many functions, such as development and research to commercial operations will observe an enormous change. Thus, this factor is anticipated to propel the market growth.
Expensive initial expenses and extended cycles for biomarker development limit the market growth.
Regional Analysis
Asia-Pacific dominated the market and is expected to maintain its dominance over the forecast period. This can be attributed to the escalation of clinical trials in emerging nations such as India and China, the surge in disease burden, and the increasing demand for therapeutics targeting the central nervous system.
Furthermore, the surge in disposable income, an expanding level of consumer awareness, and enhancements in healthcare infrastructure create a positive impact in the region. Financial progress in this region is encouraging broader adoption of biomarkers. Moreover, the development of technologically cutting-edge products aimed at lowering treatment prices and mortality rates is predicted to boost demand in the region.
North America is expected to dominate the market in terms of revenue. This is due to various factors, including the upswing in supportive government initiatives and the prevalence of neurological disorders. In addition, surge in several product introductions and an increasing demand for biomarkers. Furthermore, funding for the research and development of creative biomarkers remains robust in the region.
Segmentation Insights
Type Insight
The proteomic segment held the largest revenue share in the market. Proteomic biomarkers are necessary, particularly when messenger RNA (mRNA) expression alone cannot sufficiently reveal the functional implications of several post-translational modifications. In such instances, proteomic biomarkers become indispensable for accurately diagnosing the progression of conditions by meticulously detecting post-translational changes and protein signatures.
The metabolomic segment dominates the market. It plays an important role in determining different metabolic pathways impacted by disease treatment or progression. These biomarkers serve as indicators of the end products of continuous biological processes within tissues, cells, and organs. Famous instances include creatine, choline, and lactate which find utility in epilepsy diagnosis.
Application Insight
Alzheimer's disease dominates the market over the forecast period. This is due to the surge in prevalence of the disease and the increasing focus on early diagnosis and convenient treatment. According to the Alzheimer's Association, the global population of people living with dementia is predicted indicating a growth to 78 million by 2030 and approximately 139 million by 2050.
Prominent Companies
Segmentation Outline
The global neurological biomarkers market segmentation focuses on Type, Application, End Use, and Region.
By Type
By Application
By End Use
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL NEUROLOGICAL BIOMARKERS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: NEUROLOGICAL BIOMARKERS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL NEUROLOGICAL BIOMARKERS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE
5.1 OVERVIEW
5.2 METABOLOMIC
5.3 GENOMIC
5.4 IMAGING
5.5 PROTEOMIC
5.6 OTHERS
6 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION
6.1 OVERVIEW
6.2 AUTISM SPECTRUM DISORDER
6.3 PARKINSON'S DISEASE
6.4 ALZHEIMER'S DISEASE
6.5 MULTIPLE SCLEROSIS
6.6 OTHERS
7 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY END USE
7.1 OVERVIEW
7.2 INDEPENDENT CLINICAL DIAGNOSTIC CENTERS
7.3 RESEARCH ORGANIZATIONS AND OTHERS
7.4 HOSPITAL & HOSPITAL LABORATORIES
8 GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL NEUROLOGICAL BIOMARKERS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 ABBOTT
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ALSERES PHARMACEUTICALS INC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 BANYAN BIOMARKERS INC
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 BIO-RAD LABORATORIES INC
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 DIAGENIC ASA
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 JOHNSON & JOHNSON SERVICES INC
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 MERCK & CO INC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 MYRIAD GENETICS INC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 QUANTERIX
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 THERMO FISHER SCIENTIFIC INC
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved